Early versus Late Caffeine Therapy Administration in Preterm Neonates: An Updated Systematic Review and Meta-Analysis

Abstract

<b><i>Background:</i></b> Caffeine is commonly used as therapy for apnea of prematurity and has shown potential in preventing other conditions in preterm neonates. However, the optimal timing for caffeine therapy remains uncertain. <b><i>Objective:</i></b> This study aimed to compare the outcomes of early versus late administration of caffeine in preterm neonates. <b><i>Methods:</i></b> PubMed, Embase, and Cochrane Library were searched for studies comparing 0–2 days to ≥3 days caffeine introduction in preterm neonates. Outcomes included were mortality, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), patent ductus arteriosus (PDA), late-onset sepsis, length of hospital stay, and the composite of BPD or death. RevMan 5.4.1 was used for statistical analysis. <b><i>Results:</i></b> A total of 122,579 patients from 11 studies were included, 2 were randomized controlled trials (RCTs), and 63.9% of the neonates received early caffeine administration. The rates of BPD (OR: 0.70; 95% CI: [0.60–0.81]; <i>p</i> < 0.0001), IVH (OR: 0.86; 95% CI: [0.82–0.90]; <i>p</i> < 0.0001), ROP (OR: 0.80; 95% CI: [0.74–0.86]; <i>p</i> < 0.0001), late-onset sepsis (OR: 0.84; 95% CI: [0.79–0.89]; <i>p</i> < 0.00001), and PDA (OR: 0.60; 95% CI: [0.47–0.78]; <i>p</i> < 0.0001) were significantly reduced in the early caffeine group. The composite outcome of BPD or death was also lower in the early caffeine group (OR: 0.76; 95% CI: [0.66–0.88]; <i>p</i> < 0.0003). Mortality rate was higher in the early caffeine group (OR: 1.20; 95% CI: 1.12–1.29; <i>p</i> < 0.001). <b><i>Conclusion:</i></b> As compared with late caffeine administration, early caffeine is associated with a reduction in BPD, IVH, ROP, late-onset sepsis, and PDA in preterm neonates, albeit increased mortality. Additional RCTs are warranted to confirm these findings and evaluate whether the effect on mortality may be related to survival bias in observational studies favoring the late treatment group.